Biological E Limited (BioE or the “Company”), based in Hyderabad, India, develops and manufactures vaccines which are supplied within India and to other developing and middle-income countries either directly or through supplies to United Nations Children’s Fund (UNICEF) and the Global Alliance for Vaccines and Immunizations (GAVI). The Company is World Health Organization (WHO) pre-qualified for the liquid pentavalent vaccine (LPV) and the Japanese encephalitis (JE) vaccine. In pharmaceuticals, the Company manufactures generic formulations for the Indian market.

 The Company is now aiming to scale up its product offerings to include a wider range of vaccines and is setting up new manufacturing facilities in Shameerpet, Hyderabad, India for these products (the “Project).

 Immunization prevents illnesses from vaccine-preventable diseases, thus aiding in prevention of disability and death, in addition to lowering costs of healthcare and preventing productivity losses due to these illnesses. India’s Universal Immunization Programme (UIP), introduced in 1985, has made great progress in expanding Routine Immunization (RI) coverage across the country, and today, it is one of the largest programmes of its kind in the world. The Project will support a research-driven mid-cap company to diversify its product range and increase access to good quality affordable vaccines in India and other developing countries, create direct and indirect jobs and increase manufacturing capacity in India.